Insights

Three Routes to Pre-Licensing Access: Compassionate Use, NPP and Off-Label Use

How can an innovative medicine reach patients before Turkish licensing? The boundaries of compassionate use, named-patient supply and off-label use — and what they mean for companies.

Read →

Definition, Data, Coordination: How Türkiye Is Building Its Rare-Disease Infrastructure

From the Directorate to the National Action Plan, from the Rare Disease Data System to e-Nabız integration and the ICD coding gap — the full map of Türkiye's rare-disease state architecture from two summit reports.

Read →